Archive
555 articles, sorted by publication time.
An arXiv preprint introduces BioResearcher: it does not merely answer questions, but connects literature, trials, patents, and multi-omics data into translational-medicine files with sources, disagreements, and rankings. Beyond its strong benchmark results, the real test is whether such systems can be trusted in clinical R&D workflows.
What appears to be an Indian pharmaceutical stock-market rally is in fact rooted in the fragility of the cancer treatment supply chain: when quality and capacity fall out of balance at the same time for inexpensive, mature, irreplaceable chemotherapy drugs, the pressure reaches the clinic before it reaches the capital market.
REGEN4HD is moving neural stem cell therapy from the laboratory to the clinic, but the appearance of the first participant is only the starting point of a long clinical road. The real questions remain safety, survival and integration, and whether the course of the disease can be rewritten.
A timeline after drug approval is exposing a challenge for healthcare equality in Europe: the same innovative medicine, after crossing the regulatory threshold, may still face sharply different fates in different countries, prolonged by waiting, pricing, and budgets.
DelveInsight’s latest pipeline review shows that Parkinson’s disease R&D is moving from simply relieving symptoms toward more complex disease modification and neuroprotection; but the large number of candidate drugs still has to pass multiple tests involving clinical endpoints, disease heterogeneity, and regulatory standards.
Releasing platform information ahead of a major biotech conference can help a company gain visibility; but the true dividing line in cancer immunotherapy is not the platform name, but target selection, clinical evidence, and the boundaries of safety.
This deal is not just another large pharmaceutical company buying another clinical pipeline; it pushes the next round of competition in atopic dermatitis, asthma, and eosinophilic esophagitis toward the question of fewer doses and longer treatment intervals.
Progress in pancreatic cancer treatment has long been difficult, and a new strategy targeting IL1RAP is preparing to move into human trials; information remains limited for now, and the real questions will be safety, patient selection, and early efficacy signals.
elecoglipron delivered double-digit weight loss in a mid-stage trial, bringing AstraZeneca closer to the oral obesity drug market; but efficacy, tolerability, and differences from similar drugs will only become truly clear in Phase 3.
Insilico Medicine and SK Biopharmaceuticals are pushing AI drug design into the high-risk area where the central nervous system and immunity intersect; the real weight of this deal lies not in its maximum value, but in whether human evidence can be used step by step to unlock milestones after a small upfront payment.
The new collaboration between Insilico and SK Biopharmaceuticals brings generative AI into the difficult terrain where the central nervous system and immunity intersect; what will truly be tested is not only whether algorithms can generate molecules, but whether those molecules can find a credible biological position in human disease.
A closely watched lung cancer drug failed to meet its target in a clinical trial, dealing a setback to Pfizer’s oncology strategy; but before the full data are released, the real impact will still depend on the extent of the miss, safety signals, and subsequent subgroup analyses.